Stay updated with breaking news from Ivir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.28, Briefing.com reports. Vir Biotechnology had a negative return on equity of 33.82% and a negative net margin of 713.69%. The business had […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) rose 8.5% on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $11.28 and last traded at $11.18. Approximately 290,356 shares changed hands during trading, a decline of 73% from the average daily volume of 1,084,488 shares. The stock had […]
By Sabela Ojea Vir Biotechnology said Chief Medical Officer Phil Pang will be leaving the company at the end of March. The immunology company on Tuesday said...
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages […]
Vir Biotechnology (NASDAQ:VIR – Free Report) had its price objective trimmed by HC Wainwright from $95.00 to $85.00 in a research report report published on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Vir Biotechnology’s Q1 2024 earnings at ($0.99) EPS, Q2 2024 […]